Niagen Bioscience Subsidiary Signs Supply Agreement
I'm PortAI, I can summarize articles.
Niagen Bioscience's subsidiary, ChromaDex, Inc., has signed a Supply Agreement with W. R. Grace & Co.-Conn for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL), effective April 1, 2025, and lasting until April 30, 2029. The agreement includes automatic renewal provisions and a minimum annual purchase requirement. Analysts rate NAGE stock as a Buy with a $6.00 price target, although technical analysis shows bearish momentum and potential overvaluation concerns. Niagen Bioscience focuses on NRCL production, with a current market cap of $763.3M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments